1. Porst H, Burnett A, Brock G, et al. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med. 2013;10(1):130-171. doi:10.1111/jsm.12023
2. Meller SM, Stilp E, Walker CN, et al. The link between vasculogenic erectile dysfunction, coronary artery disease, and peripheral artery disease: role of metabolic factors and endovascular therapy. J Invasive Cardiol. 2013;25(6):313-319.
3. Raheem OA, Su JJ, Wilson JR, et al. The association of erectile dysfunction and cardiovascular disease: a systematic critical review. Am J Mens Health. 2017;11(3):552-563. doi:10.1177/1557988316630305
4. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170(2 Pt 2)S46-S50. doi:10.1097/01.ju.0000075055.34506.59
5. Montorsi F, Salonia A, Deho F, et al. Pharmacological management of erectile dysfunction. BJU Int. 2003;91(5):446-454. doi:10.1046/j.1464-410x.2003.04093.x
6. Sood R, Sharma D, Goel H, et al. The correlation between erectile dysfunction and metabolic syndrome in an Indian population: a cross-sectional observational study. Arab J Urol. 2019;17(3):221-227. doi:10.1080/ 2090598X.2019.1600990
7. Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M-23M. doi:10.1016/j.amjcard. 2005.07.006
8. Bouhanick B, Blacher J, Huyghe E. Sexual dysfunction and antihypertensive treatment: involvement of the different therapeutic classes and what to do about the treatment of hypertension. Presse Med. 2019;48(11 Pt 1):1222-8. doi:10.1016/j.lpm.2019.05.029
9. Aydın F, Bektur S, Taşdelen Y, et al. How does ivabradine effect erectile dysfunction in patients with heart failure? Kardiol Pol. 2017;75(9):893-898. doi:10.5603/KP.a2017.0095
10. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
11. Codolosa JN, Acharjee S, Figueredo VM. Update on ranolazine in the management of angina. Vasc Health Risk Manag. 2014;10:353-362. doi: 10.2147/VHRM.S40477
12. Cattaneo M, Porretta AP, Gallino A. Ranolazine: drug overview and possible role in primary microvascular angina management. Int J Cardiol. 2015;181:376-381. doi:10.1016/j.ijcard.2014.12.055
13. Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Philadelphia, PA: W.B. Saunders; 1948.
14. Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol. 2000;163(2):460-463. doi:10. 1016/S0022-5347(05)67900-1
15. Rehberger-Likozar A, Šebeštjen M. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Coron Artery Dis. 2015;26(8):651-656. doi:10.1097/MCA. 0000000000000272
16. Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017;2(2): CD011747. doi:10.1002/14651858.CD011747.pub2
17. Cappelleri JC, Rosen RC. The Sexual Health Inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005; 17(4):307-319. doi:10.1038/sj.ijir.3901327
18. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 1994;151(1):54-61. doi:10.1016/s0022-5347(17)34871-1
19. Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease. Cardiovasc Res. 1999;43(3):658-665. doi:10.1016/s0008-6363(99) 00135-2
20. De Angelis L, Marfella MA, Siniscalchi M, et al. Erectile and endothelial dysfunction in type II diabetes: a possible link. Diabetologia. 2001;44(9): 1155-1160. doi:10.1007/s001250100616
21. Junemann KP, Aufenanger J, Konrad T, et al. The effect of impaired lipid metabolism on the smooth muscle cells of rabbits. Urol Res. 1991;19(5): 271-275. doi:10.1007/BF00299056
22. Baumhäkel M, Custodis F, Schlimmer N, et al. Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE--knockout mice. Atherosclerosis. 2010;212(1):55-62, doi:10.1016/j.atherosclerosis.2010.03.002
23. Deshmukh SH, Patel SR, Pinassi E, et al. Ranolazine improves endothelial function in patients with stable coronary artery disease. Coron Artery Dis. 2009;20(5):343-347. doi:10.1097/MCA.0b013e32832a198b
24. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342(24):1802-1813. doi: 10.1056/NEJM200006153422407
25. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovas- cular patient: endothelial dysfunction is the common denominator. Heart. 2003;89(3):251-253. doi:10.1136/heart.89.3.251
26. Aldakkak M, Camara AK, Heisner JS, et al. Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol Res. 2011;64(4):381-392. doi:10.1016/j.phrs.2011.06.018
27. Pérez FR, Venegas F, González M, et al. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension. 2009;53(6):1000-1007. doi:10.1161/HYPERTENSIONAHA.108.128520